NO962538L - 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister - Google Patents

6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister

Info

Publication number
NO962538L
NO962538L NO962538A NO962538A NO962538L NO 962538 L NO962538 L NO 962538L NO 962538 A NO962538 A NO 962538A NO 962538 A NO962538 A NO 962538A NO 962538 L NO962538 L NO 962538L
Authority
NO
Norway
Prior art keywords
imidazolinylamino
unsubstituted
compounds useful
adrenoceptor agonists
quinoxaline compounds
Prior art date
Application number
NO962538A
Other languages
English (en)
Other versions
NO962538D0 (no
Inventor
Peter Julian Maurer
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO962538D0 publication Critical patent/NO962538D0/no
Publication of NO962538L publication Critical patent/NO962538L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører metoder for å behandle nasal kongestion som omfatter å administrere, til et menneske eller lavere dyr med behov for slik behandling, en sikker og effektiv mengde av en forbindelse med struktur formel (I), hvor a) R er usubstituert C^-Cj alkanyl eller alkenyl, og b) R' er valgt fra hydrogen, usubstituert Cj-Cj alkanyl eller alkenyl, usubstituert Cj-C-j alkyltio eller alkoksy, hydroksy, tiol og halo. Oppfinnelsen vedrører også anvendelse av slike for- bindelser for å forebygge eller behandle andre respira- toriske, okulære og/eller gastrointestinale lidelser.
NO962538A 1993-12-17 1996-06-14 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister NO962538L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16978593A 1993-12-17 1993-12-17
PCT/US1994/014291 WO1995016449A1 (en) 1993-12-17 1994-12-15 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
NO962538D0 NO962538D0 (no) 1996-06-14
NO962538L true NO962538L (no) 1996-08-13

Family

ID=22617165

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962538A NO962538L (no) 1993-12-17 1996-06-14 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister

Country Status (22)

Country Link
US (1) US5834470A (no)
EP (1) EP0735877B1 (no)
JP (1) JPH09506622A (no)
CN (1) CN1137755A (no)
AT (1) ATE194771T1 (no)
AU (1) AU701233B2 (no)
BR (1) BR9408342A (no)
CA (1) CA2179006A1 (no)
CZ (1) CZ175496A3 (no)
DE (1) DE69425334T2 (no)
DK (1) DK0735877T3 (no)
ES (1) ES2150546T3 (no)
FI (1) FI962493A (no)
GR (1) GR3034497T3 (no)
HU (1) HUT76283A (no)
NO (1) NO962538L (no)
PE (1) PE38195A1 (no)
PT (1) PT735877E (no)
SG (1) SG44628A1 (no)
SK (1) SK77396A3 (no)
TW (1) TW318141B (no)
WO (1) WO1995016449A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) † 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
DE69732244T2 (de) * 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
CN1244864A (zh) * 1996-11-25 2000-02-16 普罗克特和甘保尔公司 用作α－2肾上腺素能受体兴奋剂的2－咪唑啉基氨基吲唑化合物
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
ES2239466T3 (es) * 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20080241290A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Sinus relief composition and method of producing the same
US20130115320A1 (en) 2007-03-30 2013-05-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US20090069446A1 (en) * 2007-09-06 2009-03-12 Wayne Jeffrey Perry Dendritic salt therapeutic agent delivery system
US20090069433A1 (en) * 2007-09-10 2009-03-12 Wayne Jeffrey Perry Nasal rinse additive
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2843251A1 (en) 2011-07-25 2013-01-31 Santosh C. Sinha N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) * 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) * 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
JPS57501378A (no) * 1980-09-05 1982-08-05
FR2521140A1 (fr) * 1982-02-05 1983-08-12 Synthelabo Derives d'imidazolidine, leur preparation et leur application en therapeutique
FR2638356A1 (fr) * 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5096916A (en) * 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
HU9601662D0 (en) 1996-08-28
AU701233B2 (en) 1999-01-21
FI962493A0 (fi) 1996-06-14
PT735877E (pt) 2000-12-29
SK77396A3 (en) 1997-01-08
US5834470A (en) 1998-11-10
DE69425334T2 (de) 2001-02-08
EP0735877B1 (en) 2000-07-19
SG44628A1 (en) 1997-12-19
DK0735877T3 (da) 2000-11-06
EP0735877A1 (en) 1996-10-09
WO1995016449A1 (en) 1995-06-22
ATE194771T1 (de) 2000-08-15
CZ175496A3 (en) 1996-11-13
JPH09506622A (ja) 1997-06-30
BR9408342A (pt) 1997-08-19
ES2150546T3 (es) 2000-12-01
NO962538D0 (no) 1996-06-14
CA2179006A1 (en) 1995-06-22
GR3034497T3 (en) 2000-12-29
TW318141B (no) 1997-10-21
PE38195A1 (es) 1995-11-27
FI962493A (fi) 1996-07-26
CN1137755A (zh) 1996-12-11
DE69425334D1 (de) 2000-08-24
HUT76283A (en) 1997-07-28
AU1306195A (en) 1995-07-03

Similar Documents

Publication Publication Date Title
NO962538D0 (no) 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister
NO962537D0 (no) 7-(2-imidazolinylamino)kinolin-forbindelser anvendbare som -2-adrenoceptor-agonister
MY131696A (en) 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
HK1013072A1 (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists